Literature DB >> 24105455

Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure.

Chun-Hua Wang1, Fu-Tsai Chung, Shu-Min Lin, Shu-Yi Huang, Chun-Liang Chou, Kang-Yun Lee, Tzou-Yien Lin, Han-Pin Kuo.   

Abstract

OBJECTIVES: Severe H1N1 pneumonia with acute respiratory failure results in infiltration of lungs due to the presence of hyperactive immune cells. Rapamycin and corticosteroids inhibit this immune response by blocking the activation of T and B cells.
DESIGN: Open-label prospective randomized controlled trial.
SETTING: A tertiary medical center, Chang Gung Memorial Hospital, located in Taiwan. PATIENTS: Between 2009 and 2011, of 4,012 H1N1-infected patients, 38 patients with severe H1N1 pneumonia and acute respiratory failure were enrolled.
MEASUREMENTS AND MAIN RESULTS: Thirty-eight patients with confirmed H1N1 pneumonia and on mechanical ventilatory support were randomized to receive adjuvant treatment of corticosteroids with an mTOR inhibitor, either with sirolimus (Rapamune 2 mg/d) (sirolimus group, n = 19) for 14 days or without sirolimus (nonsirolimus group, n = 19). The clinical values measured included PaO2/FIO2, Sequential Organ Failure Assessment score, duration of ventilatory support, and mortality. The baseline demography was similar between the two groups. After treatment, the PaO2/FIO2 values on day 3 (167.5 [95% CI, 86.7-209.2 mm Hg], n = 19 vs 106.8 [95% CI, 73.0-140.7 mm Hg], n = 19; p = 0.025] and day 7 (241.6 [95% CI, 185.2-297.9 mm Hg], n = 19 vs 147.0 [95% CI, 100.7-193.7 mm Hg], n = 17; p = 0.008) in the sirolimus group were significantly better over the nonsirolimus group. Similarly, the Sequential Organ Failure Assessment score on day 3 (4.3 [95% CI, 3.1-5.5]; p = 0.029) and day 7 (5.9 [95% CI, 4.8-6.9], n = 19 and 6.2 [95% CI, 4.7-7.8], n = 17, respectively) significantly improved in the sirolimus group. The liberation from a mechanical ventilator at 3 months was also better in the sirolimus combined with corticosteroids treatment. Similarly, the duration of ventilator use was significantly shorter in the sirolimus group (median, 7 vs 15 d; p = 0.03 by log-rank test). In the sirolimus combined with corticosteroids treatment group, a rapid clearance of virus also occurred after 7 days of treatment.
CONCLUSIONS: In patients with severe H1N1 pneumonia, early adjuvant treatment with corticosteroids and an mTOR inhibitor was associated with improvement in outcomes, such as hypoxia, multiple organ dysfunction, virus clearance, and shortened liberation of ventilator and ventilator days.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24105455     DOI: 10.1097/CCM.0b013e3182a2727d

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  61 in total

1.  Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.

Authors:  Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng
Journal:  Cell Discov       Date:  2020-03-16       Impact factor: 10.849

2.  Mitogenic stimulation accelerates influenza-induced mortality by increasing susceptibility of alveolar type II cells to infection.

Authors:  Nikolaos M Nikolaidis; John G Noel; Lori B Pitstick; Jason C Gardner; Yasuaki Uehara; Huixing Wu; Atsushi Saito; Kara E Lewnard; Huan Liu; Mitchell R White; Kevan L Hartshorn; Francis X McCormack
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

Review 3.  Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.

Authors:  John H Beigel; Hannah H Nam; Peter L Adams; Amy Krafft; William L Ince; Samer S El-Kamary; Amy C Sims
Journal:  Antiviral Res       Date:  2019-04-08       Impact factor: 5.970

4.  Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.

Authors:  Jennifer L McKimm-Breschkin; Shibo Jiang; David S Hui; John H Beigel; Elena A Govorkova; Nelson Lee
Journal:  Antiviral Res       Date:  2017-11-21       Impact factor: 5.970

Review 5.  Corticosteroids for severe influenza pneumonia: A critical appraisal.

Authors:  Wagner Luis Nedel; David Garcia Nora; Jorge Ibrain Figueira Salluh; Thiago Lisboa; Pedro Póvoa
Journal:  World J Crit Care Med       Date:  2016-02-04

6.  Potential Drug Strategies to Target Coronaviruses.

Authors:  Kasturi Sarkar; Parames C Sil
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Rapamycin Does Not Impede Survival or Induction of Antibody Responses to Primary and Heterosubtypic Influenza Infections in Mice.

Authors:  Justine S Liepkalns; Aseem Pandey; Amelia R Hofstetter; Amrita Kumar; Enitra N Jones; Weiping Cao; Feng Liu; Min Z Levine; Suryaprakash Sambhara; Shivaprakash Gangappa
Journal:  Viral Immunol       Date:  2016-07-22       Impact factor: 2.257

8.  Administration of a CXC Chemokine Receptor 2 (CXCR2) Antagonist, SCH527123, Together with Oseltamivir Suppresses NETosis and Protects Mice from Lethal Influenza and Piglets from Swine-Influenza Infection.

Authors:  Harshini K Ashar; Sivasami Pulavendran; Jennifer M Rudd; Prasanthi Maram; Mallika Achanta; Vincent T K Chow; Jerry R Malayer; Timothy A Snider; Narasaraju Teluguakula
Journal:  Am J Pathol       Date:  2021-01-14       Impact factor: 4.307

Review 9.  Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection.

Authors:  Subhajit Maity; Abhik Saha
Journal:  Front Microbiol       Date:  2021-05-14       Impact factor: 5.640

Review 10.  Targeting immunometabolism to treat COVID-19.

Authors:  Shane M O'Carroll; Luke A J O'Neill
Journal:  Immunother Adv       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.